• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Avalyn Pharma touts study of aerosolized pulmonary fibrosis treatment

May 24, 2021 By Sean Whooley

Avalyn PharmaAvalyn Pharma announced today that it observed statistically significant success in a study of its aerosolized pulmonary fibrosis treatment.

Seattle-based Avalyn presented data from a 24-week Phase 1/2 clinical study at the ISAM conference in Boise, Idaho. The data covered two dose regimens of AP01, a formulation of pirfenidone optimized for delivery through inhalation in patients with idiopathic pulmonary fibrosis (IPF), according to a news release.

The trial randomized 90 patients with IPF to 50 mg doses once daily or 100 mg twice daily, all administered by PARI Pharma’s investigational eFlow nebulizer.

Across 24 weeks, the high dose group registered, on average, no loss of lung function as measured by forced vital capacity (FVC), while the low dose group had a progressive loss of lung function, with the difference proving statistically significant, Avalyn said.

AP01 was safe and well-tolerated in both dosing regimens, while flu-like symptoms and adverse events commonly attributed to oral pirfenidone treatment occurred in less than 10% of patients treated with the therapeutic. The most common adverse events were rash (18% of patients), upper respiratory tract infection (18%) and cough (24%).

Most subjects opted to continue in a 12-month extension of the trial, with the company planning to present long-term efficacy and safety data at an upcoming scientific meeting.

“We are pleased by the efficacy and safety profile we have seen to date with aerosolized pirfenidone in 91 patients over 24 weeks. The six-month FVC data is very promising as well as the overall safety profile to date,” Avalyn Pharma CEO Dr. A. Bruce Montgomery said in the release.

“Despite the 2014 approval of two oral antifibrotic therapies, IPF and other fibrotic lung diseases remain fatal disorders with substantial unmet need. We hope to confirm improved tolerability and long-term efficacy with aerosolized pirfenidone in future Phase 3 trials.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Avalyn Pharma

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS